Initiation of symptomatic therapy in Parkinson's disease: Dopamine agonists versus levodopa

Journal of Neurology

Volumn 254, Issue SUPPL. 5, 2007, Pages 19-26

  Lev, Nirit ^a   Djaldetti, Ruth ^a   Melamed, Eldad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dopamine agonists; Levodopa; Parkinson's disease; Treatment

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BROMOCRIPTINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; U 91356A; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DYSKINESIA; DYSTONIA; HUMAN; LABORATORY TEST; LIFE EXPECTANCY; MONOTHERAPY; MORBIDITY; MOTOR DYSFUNCTION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

EID: 34548799803     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-5004-8     Document Type: Conference Paper

References (62)

1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393-399
2. Barone P, Bravi D, Bernejo-Pareja F, Marconi R, Kulisevsky J, Malagù S, Weiser R, Rost N (1999) Pergolide monotherapy in the treatment of early PD: a randomized controlled study. Neurology 53:573-579
3. Bedard PJ, Di Paolo, Falardeau P, Boucher R (1986) Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379:294-299
4. Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 95:979-983
5. Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, Piercey MF (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854-859
6. Block G, Liss C, Scott R, Irr J, Nibbelink D (1997) Comparison of immediaterelease and controlled release carbidopa/ levodopa in Parkinson's disease.A multicenter 5-year study. Eur Neurol 37:23-27
7. Cassarino DS, Fall CP, Smith TS, Bennet JP Jr (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301
8. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). J Neurol Sci 78:273-280
9. Corrigan MH, Denahan AQ, Eugene Wright C, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58-65
10. Datla KP, Blunt SB, Dexter D (2001) Chronic L-dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-hydroxydopamine or FeCl3 nigrostriatal lesions. Mov Disord 16:424-434
11. Djaldetti R, Inzelberg R, Giladi N, Korczyn AD, Peretz-Aharon Y, Rabey MJ, Herishano Y, Honigman S, Badarny S, Melamed E (2002) Oral solution of levodopa ethyl ester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 17:297-302
12. Dupont E, Anderson A, Boqs J, Boisen E, Borgmann R, Helgetveit AC, Kjaer AC, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93:14-20
13. Etminan M, Samii A, Takkouche B, Rochon P (2001) Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease. A meta-analysis of randomised controlled trials. Drug Safety 24:863-868
14. Freeman AS, Meltzer LT, Bunney BS (1985) Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci 36:1983-1994
15. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
16. Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001-2004. Mov Disord 20:523-539
17. 2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drugnaïve primates. Brain Res 735:298-306
18. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287:455-463
19. Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, Wenning G, Poewe W (2003) Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 18:319-323
20. Jenner P (2002) Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 (Suppl 1):S1-S8
21. Johnson SW, Seutin V, North RA (1992) Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 258:665-667
22. King DF, Cooper JM, Schapira AHV (2001) Pramipexole protects against MPP + toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 56:A377-A388
23. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T (1998) Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-I and CPP32, in Alzheimer's disease. Brain Res 780:260-269
24. Koller WC (2002) Treatment of early Parkinson's disease. Neurology 58 (Suppl 1):S79-S86
25. Lees AJ, Katzenschlager R, Head J, Ben- Shlomo Y, on behalf of the Parkinson's Disease Research Group on the United Kingdom (2001) Ten-year follow-up of three different initial treatments in denovo PDA randomized trial. Neurology 57:1687-1694
26. Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I (1998) Levodopa toxicity and apoptosis. Ann Neurol 44:S149-S154
27. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard JM, Rascol O, Brefel-Courbon C (2001) Long-term mortality results on the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 16:511-514
28. Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomized controlled study comparing bromocriptine to which levodopa was later added, versus levodopa alone in patients with Parkinson's disease: A five year follow-up. J Neurol Neurosurg Psychiatry 57:1034-1038
29. Murer MG, Dziewczapolski G, Menalled LB, García MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopaminergic neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561-575
30. Mytilineou C, Han SK, Cohen G (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61:1470-1478
31. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW (2000) Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47(Suppl):S22-S34
32. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21:343-353
33. Ogawa N, Tanaka K-I, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657:207-213
34. Okun MS, Watts RL (2002) Depression associated with Parkinson's disease. Neurology 58(Suppl 1):S63-S70
35. Olanow CW, Schapira AHV, Rascol O (2000) Continuous dopamine receptor stimulation in early Parkinson's disease. Trends Neurosci 23(Suppl):S117-S126
36. Olanow CW (2002) The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58:S33-S41
37. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O,Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19:997-1005
38. Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 278:125-130
39. Parkinson Study Group (2000) Pramipexole versus levodopa as initial treatment for Parkinson's disease. JAMA 284:1931-1938
40. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287:1653-1661
41. Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
42. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18:659-667
43. Pearce PKB, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13:234-241
44. Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 10:731-740
45. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491
46. Rascol O, Payoux, P, Ferreira J, Brefel-Courbon C (2002) The management of patients with early Parkinson's disease. Parkinsonism Relat Disord 9:61-67
47. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53(Suppl 3):S3-S15
48. Razmy A, Lang AE, Shapiro CM (2004) Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61:97-102
49. Rinne UK (1987) Brief communications. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a five year follow-up. Neurology 37:826-828
50. Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39:336-339
51. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double blind levodopa controlled trial. Drugs 55(Suppl 1):S23-S30
52. Schapira AHV (2002) Neuroprotection and dopamine agonists. Neurology 58(Suppl 1):S9-S18
53. Schapira AHV, Olanow CW, Isacson, Rascol, Brooks, Tatton, Marek, Beal, Jenner (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 53(Suppl 3):S149-S159
54. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123:2297-2305
55. Shannon KM, Bennet JP, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49:724-728
56. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112-2122
57. Spencer JP, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 66:1480-1484
58. Spina MB, Cohen G (1988) Exposure of striatal synaptosomes to l-dopa elevates levels of oxidized glutathione. J Pharmacol Exp Ther 247:502-507
59. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179-1183
60. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464
61. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 54:93-101
62. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62:1034-1038